This proposal is designed to test the protein leverage hypothesis (PLH) in humans: the idea that the level of food consumption in humans, like other animals, is adjusted to maintain a target protein intake. As the prevalence of overweight and obesity increases, with its attendant health problems, the need to identify which dietary components limit rather than exacerbate energy intake is imperative. According to the PLH, the consumption of a diet low in % protein and high in % fat and carbohydrat ....This proposal is designed to test the protein leverage hypothesis (PLH) in humans: the idea that the level of food consumption in humans, like other animals, is adjusted to maintain a target protein intake. As the prevalence of overweight and obesity increases, with its attendant health problems, the need to identify which dietary components limit rather than exacerbate energy intake is imperative. According to the PLH, the consumption of a diet low in % protein and high in % fat and carbohydrate, typical of many Western countries, inevitably requires the ingestion of additional energy to maintain protein intake constant, thus driving weight gain. Conversely, the consumption of a diet that is relatively high in % protein requires the ingestion of lower levels of energy, creating the potential for weight loss. Preliminary experimental and population-level nutritional survey data support the PLH, as does the finding that protein is more satiating than other macronutrients. If, as predicted, small changes in the proportion of protein in diets described in the current study are found to impact on total energy intake there will be significant implications for weight control strategies. Thus, if the PLH is confirmed, public health dietary recommendations and government policy settings for the food industry will need to change. Large-scale intervention studies aimed at demonstrating the longer term impact on body weight will also be required.Read moreRead less
The OUTBACK Trial - The Role Of Adjuvant Chemotherapy In Locally Advanced Cervical Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,472,782.00
Summary
This international randomized phase III trial will test the value of giving additional chemotherapy treatment to women with locally advanced cervix cancer following standard chemo-radiation treatment. The aim is to improve survival rates for these women, many of whom have a 40% or greater chance of their disease relapsing after treatment. The trial has been designed in Australia, and is open in multiple countries with Australia New Zealand Gynaecological Oncology Group (ANZGOG) as the lead group ....This international randomized phase III trial will test the value of giving additional chemotherapy treatment to women with locally advanced cervix cancer following standard chemo-radiation treatment. The aim is to improve survival rates for these women, many of whom have a 40% or greater chance of their disease relapsing after treatment. The trial has been designed in Australia, and is open in multiple countries with Australia New Zealand Gynaecological Oncology Group (ANZGOG) as the lead group.Read moreRead less
Benefits Of Home-based Multidisciplinary Rehabilitation In Non Small Cell Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$581,039.00
Summary
Lung cancer is the third leading cause of death in Australia. People with lung cancer experience a complex mix of symptoms that can provoke significant distress and impair physical function. This study aims to develop and test a home based exercise and self-management support program to increase function and physical activity levels, reduce levels of depression and improve quality of life of people with lung cancer.
Cardiac Resynchronisation Therapy And AV Node Ablation For Atrial Fibrillation In Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$3,274,979.00
Summary
Heart failure (HF) and Atrial Fibrillation (AF) are both significant health issues that often coexist. Cardiac resynchronisation therapy (CRT) is a proven therapy for HF with ventricular dyssynchrony (uncoordinated contraction of the left ventricle). While CRT reduces symptoms and improves survival in normal rhythm, there are mixed reports in patients with AF. This prospective randomised multicentre study, will assess the role of AV node ablation to improve outcomes in CRT in AF.